Avingtrans has announced this morning that CE certification has been secured for Adaptix Ortho350, a significant commercial milestone opening up human imaging markets across the UK and Europe. This follows US FDA clearance in November 2025, meaning the product is now approved in both major Western markets. To remind, Adaptix is a compact, portable, low-cost 3D Digital Tomosynthesis (DT) imaging system designed for point-of-care use. In orthopaedics, the Ortho350 delivers high-resolution, low-dose 3D imaging of extremities hands, elbows, shoulders, knees and feet offering clinicians superior diagnostic clarity versus traditional 2D X-ray at a fraction of CT radiation doses. No changes to forecasts but today’s news strengthens our confidence in the path ahead.
